These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 6350965)

  • 1. [Comparison of the therapeutic results in treating chronic myelosis with splenic irradiation or busulfan].
    Pfeilsticker U; Heidemann E; Wilms K; Voss AC; Waller HD
    Onkologie; 1983 Jun; 6(3):136-9. PubMed ID: 6350965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of chronic myeloid leukemia: a five-year survey with a comparison of oral busulfan and splenic irradiation.
    Gollerkeri MP; Shah GB
    Cancer; 1971 Mar; 27(3):596-601. PubMed ID: 5279330
    [No Abstract]   [Full Text] [Related]  

  • 3. Splenic irradiation in chronic myeloid leukemia.
    Hukku S; Baboo HA; Venkataratnam S; Vidyasagar MS; Patel NL
    Acta Radiol Oncol; 1983; 22(1):9-12. PubMed ID: 6305140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Giant nuclei after myleran therapy and spleen irradiation in chronic myeloid leukemia].
    WALLER U
    Pathol Microbiol (Basel); 1960; 23():283-90. PubMed ID: 13842627
    [No Abstract]   [Full Text] [Related]  

  • 5. Splenic irradiation following chemotherapy in chronic myelogenous leukemia.
    Wilson JF; Johnson RE
    Radiology; 1971 Dec; 101(3):657-61. PubMed ID: 5288778
    [No Abstract]   [Full Text] [Related]  

  • 6. [Letter: Comparative study of busulfan and of the combination of busulfan with splenic radiotherapy in the treatment of chronic myeloid leukemias].
    Messerschmitt J; Colonna P; Hamladji RM; Belkhodja A; Taleb A
    Nouv Presse Med; 1975 Nov; 4(39):2812. PubMed ID: 1105426
    [No Abstract]   [Full Text] [Related]  

  • 7. Survival in chronic granulocytic leukemia. Splenic irradiation vs busulfan.
    Conrad FG
    Arch Intern Med; 1973 May; 131(5):684-5. PubMed ID: 4512787
    [No Abstract]   [Full Text] [Related]  

  • 8. Spleen size and chromosome analysis as prognostic factors in chronic myelogenous leukemia.
    Collins RK; Jackson JF; Morrison FS; Meydrech EF
    South Med J; 1979 Jun; 72(6):642-4, 651. PubMed ID: 287200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced-intensity conditioning allogeneic blood stem cell transplantation with fludarabine and oral busulfan with or without pharmacokinetically targeted busulfan dosing in patients with myeloid leukemia ineligible for conventional conditioning.
    Martino R; Pérez-Simón JA; Moreno E; Queraltó JM; Caballero D; Mateos M; Sureda A; Cañizo C; Brunet S; Briones J; Vazquez L; Clopés A; San Miguel JF; Sierra J
    Biol Blood Marrow Transplant; 2005 Jun; 11(6):437-47. PubMed ID: 15931632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Observations on the therapy of chronic granulocytic leukaemia (C.G.L.) in adults.
    Das KV; Thomas M; Pilla MV; Vijayakumar
    J Assoc Physicians India; 1977 Aug; 25(8):547-53. PubMed ID: 275251
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of chronic myeloid leukemia.
    Stryckmans PA
    Annu Rev Med; 1980; 31():159-66. PubMed ID: 6994603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Busulfan, cyclophosphamide and fractionated total body irradiation for autologous or syngeneic marrow transplantation for acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels.
    Demirer T; Buckner CD; Appelbaum FR; Bensinger WI; Sanders J; Lambert K; Clift R; Fefer A; Storb R; Slattery JT
    Bone Marrow Transplant; 1996 Apr; 17(4):491-5. PubMed ID: 8722344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Splenic irradiation in the management of chronic granulocytic leukaemia.
    Jacobs P; Dubovsky D; King H; Sealy R
    Cent Afr J Med; 1975 Oct; 21(10):207-10. PubMed ID: 1059505
    [No Abstract]   [Full Text] [Related]  

  • 14. [Chronic myelogenous leukemia. Results of therapy with busulfan].
    Olesen J; Videbaek A
    Nord Med; 1969 Oct; 82(41):1284-90. PubMed ID: 5260856
    [No Abstract]   [Full Text] [Related]  

  • 15. Myeloablative versus Reduced-Intensity Conditioning in Patients with Myeloid Malignancies: A Propensity Score-Matched Analysis.
    Sibai H; Falcone U; Deotare U; Michelis FV; Uhm J; Gupta V; Kuruvilla J; Lipton JH; Seftel MD; Messner HA; Kim DDH
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2270-2275. PubMed ID: 27596129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Colcemid and myleran in the treatment of chronic myelosis].
    WILDHACK R
    Dtsch Med Wochenschr; 1957 Mar; 82(10):342-6. PubMed ID: 13427505
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase II study of busulfan, cyclophosphamide and fractionated total body irradiation as a preparatory regimen for allogeneic bone marrow transplantation in patients with advanced myeloid malignancies.
    Lynch MH; Petersen FB; Appelbaum FR; Bensinger WI; Clift RA; Storb R; Sanders JE; Hansen JA; Buckner CD
    Bone Marrow Transplant; 1995 Jan; 15(1):59-64. PubMed ID: 7742756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Chronic myeloid leukemia: comparison of monotherapy with busulfan with busulfan and vincristine and 6-mercaptopurine cycles].
    Cervantes F; Rozman C; Nomdedeu B; Blade J; Montserrat E
    Rev Clin Esp; 1986 Jan; 178(1):4-7. PubMed ID: 3457411
    [No Abstract]   [Full Text] [Related]  

  • 19. [Late results of BCG immunotherapy of myelocytic leukemia].
    Kardaszewicz E; Siejeńska L; Harbut-Gryłka A
    Pol Arch Med Wewn; 1983 Sep; 70(3):87-92. PubMed ID: 6581478
    [No Abstract]   [Full Text] [Related]  

  • 20. High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission.
    Zander AR; Berger C; Kröger N; Stockshläder M; Krüger W; Horstmann M; Grimm J; Zeller W; Kabisch H; Erttmann R; Schönrock P; Kuse R; Braumann D; Illiger HJ; Fiedler W; de Witt M; Hossfeld KD; Weh HJ
    Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2671-5. PubMed ID: 10068272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.